tetano
Editor, Senior Moderator
Radiology
. 2021 Aug 10;211396.
doi: 10.1148/radiol.2021211396. Online ahead of print.
CT of Postacute Lung Complications of COVID-19
Joshua J Solomon[SUP] 1 [/SUP], Brooke Heyman[SUP] 2 [/SUP], Jane P Ko[SUP] 3 [/SUP], Rany Condos[SUP] 2 [/SUP], David A Lynch[SUP] 4 [/SUP]
Affiliations
Abstract
The acute course of coronavirus disease 2019 (COVID-19) is variable and ranges from asymptomatic infection to fulminant respiratory failure. Patients recovering from COVID-19 can have persistent symptoms and computed tomography (CT) abnormalities of variable severity. At 3 months after acute infection, a subset of patients will have CT abnormalities that include ground glass abnormalities (GGO) and subpleural bands with concomitant pulmonary function abnormalities. At 6 months after acute infection, some patients have persistent CT changes to include the resolution of GGOs seen in the early recovery phase and the persistence or development of changes suggestive of fibrosis such as reticulation with or without parenchymal distortion. Predictors of post-COVID lung disease include need for intensive care unit (ICU) admission, mechanical ventilation, higher inflammatory markers, longer hospital stay and a diagnosis of acute respiratory distress syndrome (ARDS). Treatments of post-COVID lung disease are being investigated with anti-fibrotic agents being investigated for the prevention of post-COVID lung fibrosis. The etiology of post-COVID lung disease may be a sequela of prolonged mechanical ventilation, COVID-induced ARDS or direct injury from the virus. Future research is needed to determine the long-term persistence of post-COVID lung disease, its impact on patients and ways to prevent or treat it.
. 2021 Aug 10;211396.
doi: 10.1148/radiol.2021211396. Online ahead of print.
CT of Postacute Lung Complications of COVID-19
Joshua J Solomon[SUP] 1 [/SUP], Brooke Heyman[SUP] 2 [/SUP], Jane P Ko[SUP] 3 [/SUP], Rany Condos[SUP] 2 [/SUP], David A Lynch[SUP] 4 [/SUP]
Affiliations
- PMID: 34374591
- DOI: 10.1148/radiol.2021211396
Abstract
The acute course of coronavirus disease 2019 (COVID-19) is variable and ranges from asymptomatic infection to fulminant respiratory failure. Patients recovering from COVID-19 can have persistent symptoms and computed tomography (CT) abnormalities of variable severity. At 3 months after acute infection, a subset of patients will have CT abnormalities that include ground glass abnormalities (GGO) and subpleural bands with concomitant pulmonary function abnormalities. At 6 months after acute infection, some patients have persistent CT changes to include the resolution of GGOs seen in the early recovery phase and the persistence or development of changes suggestive of fibrosis such as reticulation with or without parenchymal distortion. Predictors of post-COVID lung disease include need for intensive care unit (ICU) admission, mechanical ventilation, higher inflammatory markers, longer hospital stay and a diagnosis of acute respiratory distress syndrome (ARDS). Treatments of post-COVID lung disease are being investigated with anti-fibrotic agents being investigated for the prevention of post-COVID lung fibrosis. The etiology of post-COVID lung disease may be a sequela of prolonged mechanical ventilation, COVID-induced ARDS or direct injury from the virus. Future research is needed to determine the long-term persistence of post-COVID lung disease, its impact on patients and ways to prevent or treat it.